News and Comments

The FDA Approval Of Kynamro™ Promises ISIS A Bright Future Read Also about ALNY; Sarepta, SNY

  Thursday, January 31, 2013

 More...

XOMA: WILL THE LOVE-HATE SKEPTICISM MARRIAGE WITH INVESTORS FINALLY ENDS UP IN A STABLE RELATIONSHIP?

  Tuesday, January 15, 2013

XOMA (XOMA) is addictive and its relationship to investors is typical of that of married couples who have a love/hate alternating history, which is interrupted with divorces and remarrying. Around a week ago, the firm announced interim data from a phase 2 proof-of-concept (POC) study on gevokizumab, which is being developed for the treatment of inflammatory facial lesions in patients suffering from moderate to severe acne vulgaris.  More...

THERAVANCE: BECAME TEMPTING TO INVESTORS ANR TO ITS PARTNER

  Monday, January 07, 2013

Using scientific skills towards building pipelines of promising products does not guarantee a happy ending for a small biotech firm. Pipelines’ breakthroughs need managements’ capabilities and swiftness of actions, which would walk them through the safest and fastest road towards approvals.  We believe Theravance (THRX) has benefited from both its scientists and management. The firm has come nearer than ever to reaching a happy beginning of substantial growth, or perhaps, a happy ending through acquisition, probably, by its partner GlaxoSmithKline (GSK).  More...


Recent Postings


Archive


Tags

Mirati Therapeutics (MRTX) Sangamo (SGMO) Xoma (XOMA) Zerenex Advaxis (ADXS) Spike Therapeutics (ONCE) Dynavax (DVAX) SERES THERAPEUTICS (MCRB) JUNO (JUNO) Sanofi (SNY) Multiple Myeloma Exelixis (EXEL) Sanofi (SNA) Intermune (ITMN) IDERA (IDRA) NANTKWEST (NK) Genentech galapagos (GLPG) VANDA (VNDA) Seattle Genetics (SGEN) Herceptin INNOVIVA (INVA) BIOMARIN (BMRN) Vitae Pharmaceuticals (VTAE) Theravance (THRX) MODERNA Human Genome Sciences (HGSI) Abbott Laboratories (ABT) CompuGen (CGEN) Agenus (AGEN HALOZYME (HALO) Inovio (INO) KERYX (KERX) Micromet (MITI) Jazz Pharmaceuticals (JAZZ) Incyte (INCY) Trastuzumab-DM1 Cytokinetics (CYTK) ZALTRAP™ Anadys (ANDS) Onyx (ONXX) Biogen Idec (BIIB) TOKAI (TKAOI) OSI (OSIP) Illumina (ILMN) Roche (RHHBY) Theravance Bio Pharma (TBPH) PTC Therapeutics (PTCT) KITE (KITE) Anacor (ANAC) Intrexon (XON) AERIE PHARMACEUTICALS Alder Biopharmaceuticals (ALDR) Ridaforolimus Agenus (AGEN) RenenxBio (RGNX) ISIS (ISIS) Ionis (IONS) Elan (ELN) Prolor Biotech (PBTH) Intercept (ICPT) Sequenom (SQNM) Prosensa (RNA) ABBVIE (ABBV) ADVENTRIX (ANX) SUNESIS PHARMACEUTICALS (SNSS) Velcade (bortezomib) Ziofpharm (ZIOP) Valeant Pharmaceuticals International (VRX) Galena (GALE) Telaprevir GUARDIAN HEALTH Rapamune Array Pharmaceuticals (ARRY) Aimmune Therapeutics (AIMT) Amgen (AMGN) Pluristem (PSTI) Auspex (ASPX) NEKTAR (NKTR)) Regeneron (REGN) REGULUS (RGLS) Merck (MRK) Ariad (ARIA) Alnylam (ALNY) Editas (EDIT) ARGOS (ARGS) Bellicum (BLCM) Global Cell Therapeutics (GBT) Vertex (VRTX) Biocryst (BCRX) NOVOCURE (NVCR) Bristol-Myers Squibb (BMY) Sarepta (SRPT) Roche (ROCHE) ARCA (ABIO) GlaxoSmithKline (GSK) Sanofi-Aventis (SAN) Benlysta (belimumab) ImmunoGen (IMGN) Gilead (GILD) Adaptimmune (ADAP) Endometrial Cancer Idenix (IDIX) Human Longevity (HLI) AstraZeneca (AZN) Dendreon (DNDN) Tysabri SYNTA (SNTA) Revlimid (lenolidamide) AGOS (ARGS) C4 Therapeutics ACADIA (ACAD)